ArticleBMC oral health2026
Chitosan-arginine/amorphous calcium phosphate nanoparticles-containing orthodontic cement: antibacterial and remineralization strategies against enamel white spot lesions.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDuring fixed orthodontic treatment, white spot lesions (WSLs) are prevalent issues associated with cariogenic bacteria. This study aimed to develop a novel orthodontic cement by incorporating a chitosan-arginine (Ch-Arg) complex and nanoparticles of amorphous calcium phosphate (NACP) into resin-modified glass ionomer cement (RMGIC), and to evaluate its antibacterial and remineralization effects for combating WSLs.
methodsCh-Arg complex was synthesized via grafting and characterized by Fourier transform infrared spectroscopy and nuclear magnetic resonance analysis. RMGIC were modified with 5 wt% NACP, 1 wt% Ch-Arg, 2 wt% Ch-Arg, 1 wt% Ch-Arg + 5 wt% NACP, 2 wt% Ch-Arg + 5 wt% NACP, and no additions were control. Curing and bonding properties were assessed with degree of conversion (DC) and shear bond strength (SBS). The release of Ca2+, PO43−, and F− were determined, and pH measurements were recorded via submerging each specimen in lactic acid solution. The remineralization effect was confirmed by enamel microhardness test. Antimicrobial activity was evaluated with Streptococcus mutans, and cytocompatibility was tested with cytotoxicity test in vitro. Data were evaluated by one-way analysis of variance, followed by the Tukey honestly significant difference post hoc test, with a significance level set at 0.05.
resultsThe 2 wt%Ch-Arg + 5 wt%NACP group showed a lower SBS value (p < 0.05), but remained within clinically acceptable threshold. For ion release, NACP addition increased Ca2+ and PO43− release, while the incorporation of either NACP or Ch-Arg did not impede sustained F− release. The NACP-containing groups showed increasing pH values and Vickers hardness at cariogenic pH levels, demonstrating acid-neutralization and remineralization property. Colony-forming unit counting and live/dead assay indicated that 2 wt%Ch-Arg + 5 wt%NACP group showed significant effect on microbial/antibiofilm growth (p < 0.05). The cell counting kit-8 test indicated no cytotoxicity, with statistically significant differences (p < 0.05).
conclusionRMGIC containing 5 wt% NACP and 2 wt% Ch-Arg exhibited optimal antimicrobial efficacy, acid-neutralization capacity, and remineralization potential, while preserving clinically acceptable bonding and curing performance. The incorporation of Ch-Arg and NACP into RMGIC demonstrated adequate mechanical strength, enhanced antibacterial and remineralization effects, and favorable cytocompatibility. This combination offers a promising strategy to address WSLs in fixed orthodontics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.